CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has received a consensus rating of “Moderate Buy” from the twenty-two ...

We recently published a list of Shares of 10 Firms Soar on Friday. In this article, we are going to take a look at where ...

Investors in CRISPR Therapeutics AG (Symbol: CRSP) saw new options begin trading today, for the April 4th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ...

Fintel reports that on February 14, 2025, Evercore ISI Group upgraded their outlook for CRISPR Therapeutics (NasdaqGM:CRSP) from In-Line to Outperform. As of January 28, 2025, the average one-year ...

In trading on Friday, shares of CRISPR Therapeutics AG (Symbol: CRSP) crossed above their 200 day moving average of $49.55, changing hands as high as $52.60 per share. CRISPR Therapeutics AG ...

On Hump Day, investors piled into CRISPR Therapeutics (NASDAQ: CRSP) stock, sending its price more than 9% higher at the trading session's close. They were highly encouraged by the specialized ...

CRISPR Therapeutics AG (CRSP) ended the recent trading session ... At the same time, the Dow added 0.38%, and the tech-heavy Nasdaq gained 0.98%. The company's shares have seen an increase of ...

CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $1.15. This compares to earnings of $1.10 per share a year ago.

Vertex teamed up with CRISPR Therapeutics (NASDAQ: CRSP) on the powerful gene-editing therapy that effectively cures both rare blood disorders. The commercial ramp-up for Casgevy is taking some ...

CRISPR Therapeutics CRSP is expected to report fourth-quarter and full-year 2024 earnings later this month. The Zacks Consensus Estimate for quarterly sales is pegged at $10.13 million ...

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) will likely be announcing its earnings results before the market opens on ...